Online inquiry

IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11512MR)

This product GTTS-WQ11512MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FGFR3 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000142.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2261
UniProt ID P22607
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11512MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3302MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ11795MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ14127MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ10111MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ7976MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ14001MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ2856MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ1014MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-383
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW